CXCL9 and neoplasm: In addition, many T cell signatures have been reported to be predictive for anti-PD1 response in a variety of tumor types, including cytolytic (Rooney et al., 2015), T cell IFN-γ-related mRNA profiles (Ayers et al., 2017), the chemokine CXCL9 (Chow et al., 2019; House et al., 2020; Litchfield et al., 2021), CD8A (Tumeh et al., 2014), and an antagonistic inflammatory phenotype (Bonavita et al., 2020).